Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02857543
Other study ID # 16-745
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2016
Est. completion date October 25, 2021

Study information

Verified date November 2021
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to investigate the effects of a PB no- added-fat and the AHA and MED in obese (BMI >95%) children ages 9-18 with hypercholesterolemia (>169 mg/dl) and a parent or guardian. Eligible patients will be identified by utilizing the Pediatric Obesity Registry. When possible, in-person discussions or phone calls with their primary or tertiary care physicians will introduce eligible patients and their parents to the study. All eligible patients and parents will receive letters describing the study and requesting their participation. Subjects can choose not to participate in the study, and their health care will not be affected in any way. Subjects not participating will be asked if they are willing to answer a brief questionnaire about why they chose not to participate. The proposed study will be carried out for a total of 52 weeks. The investigators expect to recruit a total of 180 participants (30 children and 30 parents/guardians in each of the three groups). Each child and parent/guardian pair will be randomly assigned to either PB no-added-fat, AHA or MED.


Description:

Background: There is a need to have effective lifestyle modifications that target the growing group of obese children with dyslipidemia. The beneficial health effects of plant-based (PB) diets in adults are known. Studies have suggested that a low-fat vegan diet (no animal products) may promote weight loss, lower body mass index (BMI), and improve lipoprotein profiles and insulin sensitivity and possibly prevent cardiovascular disease (CVD).1-5 Those who follow a vegetarian diet(no animal products except for dairy and/or eggs) typically have lower cholesterol levels and a lower risk for heart disease than non-vegetarians.6-8 Additionally, vegetarian diets have been shown to not only prevent but reverse heart disease in adults.9-11 The three major diets emphasized in the 2015 United States Dietary Guidelines are a Plant-based Diet (PB), and the American Heart Association-like Diet (AHA) and Mediterranean Diet (MED).(11) Similar to the PB, the AHA diet encourage fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, and lean meat and fish in moderation. The MED, is similar to AHA with more emphasis on fish and extra virgin olive oil and/or nuts). Study Aims: The primary aim of this study is to determine whether a PB and/or AHA and/or MED diets significantly change anthropometric measurements and/or biomarkers of CVD risk after a 4 and 52-week intervention in obese children with hypercholesterolemia ages 9-18 years and one of their parents. The investigators also aim to prospectively determine for the first time in children and adults if there are significant outcome differences between the three diets highlighted in the 2015 U.S. Dietary Guidelines. Protocol Summary The purpose of this research is to investigate the effects of a PB no- added-fat and the AHA and MED in obese (BMI >95%) children ages 9-18 with hypercholesterolemia (>169 mg/dl) and a parent or guardian. Eligible patients will be identified by utilizing the Pediatric Obesity Registry. When possible, in-person discussions or phone calls with their primary or tertiary care physicians will introduce eligible patients and their parents to the study. All eligible patients and parents will receive letters describing the study and requesting their participation. Subjects can choose not to participate in the study, and their health care will not be affected in any way. Subjects not participating will be asked if they are willing to answer a brief questionnaire about why they chose not to participate. The proposed study will be carried out for a total of 52 weeks. The investigators expect to recruit a total of 180 participants (30 children and 30 parents/guardians in each of the three groups). Each child and parent/guardian pair will be randomly assigned to either PB no-added-fat, AHA or MED. Procedures of the study: Eligible patients and parent/guardian pairs who are interested in participating in the study will have an initial phone call with the study team to answer any questions regarding the study. Informed consent, or assent for children under age 18, will then be obtained by study team investigators face-to-face with the parent/guardian and child pairs prior to the start of the study at a mutually convenient time and place at Cleveland Clinic Regional and Main Campus sites. Patient and parent/guardian pairs will be randomized to one of the three diets at the first study visit. Throughout the 52 week diet study, participants will be asked to attend group sessions held on Saturdays during weeks 0, 1, 2, 3, 4, and 52 to learn about their assigned diets and receive support for their efforts. There will Saturday support sessions during weeks 6, 10, 16, 24, 34, and 46 and support phone calls every 2 weeks. The participants will also provide 24 hour dietary recalls of 2 weekdays and 1 weekend day on three time points: before the first study visit, between weeks 2 and 4, and then between weeks 48 and 52. Participants will have fasting blood tests to assess biomarkers of cardiovascular risk and anthropometric measurements will be performed weeks 0, 4, and 52. Stool and urine specimens will be obtained for possible future testing for microbiome, genomic data and markers of cardiovascular risk at weeks 0, 4, and 52.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date October 25, 2021
Est. primary completion date September 30, 2017
Accepts healthy volunteers No
Gender All
Age group 9 Years to 18 Years
Eligibility Inclusion Criteria: - children ages 9-18 - obese (BMI >95%) - hypercholesterolemia (>169 mg/dl) Exclusion Criteria: - pregnant women

Study Design


Intervention

Other:
Plant-Based Diet

American Heart Association Diet

Mediterranean Diet


Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

References & Publications (12)

Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Jaster B, Seidl K, Green AA, Talpers S. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006 Aug;29(8):1777-83. — View Citation

Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. Am J Med. 2005 Sep;118(9):991-7. — View Citation

Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD? J Fam Pract. 2014 Jul;63(7):356-364b. — View Citation

Ferdowsian HR, Barnard ND. Effects of plant-based diets on plasma lipids. Am J Cardiol. 2009 Oct 1;104(7):947-56. doi: 10.1016/j.amjcard.2009.05.032. Review. — View Citation

Fraser GE. Vegetarian diets: what do we know of their effects on common chronic diseases? Am J Clin Nutr. 2009 May;89(5):1607S-1612S. doi: 10.3945/ajcn.2009.26736K. Epub 2009 Mar 25. Review. Erratum in: Am J Clin Nutr. 2009 Jul;90(1):248. — View Citation

Hu FB. Plant-based foods and prevention of cardiovascular disease: an overview. Am J Clin Nutr. 2003 Sep;78(3 Suppl):544S-551S. doi: 10.1093/ajcn/78.3.544S. Review. — View Citation

Macknin M, Kong T, Weier A, Worley S, Tang AS, Alkhouri N, Golubic M. Plant-based, no-added-fat or American Heart Association diets: impact on cardiovascular risk in obese children with hypercholesterolemia and their parents. J Pediatr. 2015 Apr;166(4):953-9.e1-3. doi: 10.1016/j.jpeds.2014.12.058. Epub 2015 Feb 12. — View Citation

Mishra S, Xu J, Agarwal U, Gonzales J, Levin S, Barnard ND. A multicenter randomized controlled trial of a plant-based nutrition program to reduce body weight and cardiovascular risk in the corporate setting: the GEICO study. Eur J Clin Nutr. 2013 Jul;67(7):718-24. doi: 10.1038/ejcn.2013.92. Epub 2013 May 22. — View Citation

Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. Erratum in: JAMA 1999 Apr 21;281(15):1380. — View Citation

Turner-McGrievy GM, Barnard ND, Scialli AR. A two-year randomized weight loss trial comparing a vegan diet to a more moderate low-fat diet. Obesity (Silver Spring). 2007 Sep;15(9):2276-81. — View Citation

Tuso PJ, Ismail MH, Ha BP, Bartolotto C. Nutritional update for physicians: plant-based diets. Perm J. 2013 Spring;17(2):61-6. doi: 10.7812/TPP/12-085. — View Citation

U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015-2020 Dietary Guidelines for Americans. 8th Edition. December 2015. Available at http://health.gov/dietaryguidelines/2015/guidelines/

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline Biomarkers of Cardiovascular Risk at 4 weeks and 52 weeks Change in lipid panel, myeloperoxidase, hs C-reactive protein, insulin, glucose, HgbA1C, ALT, AST levels at 4 weeks and 52 weeks after baseline baseline, 4 weeks, 52 weeks
Secondary Change from baseline weight at 4 weeks and 52 weeks Change in kilograms at 4 weeks and 52 weeks after baseline baseline, 4 weeks, 52 weeks
Secondary Change from baseline blood pressure at 4 weeks and 52 weeks Change in systolic blood pressure in mm Hg at 4 weeks and 52 weeks after baseline baseline, 4 weeks, 52 weeks
Secondary Change in baseline waist circumference at 4 weeks and 52 weeks Change in centimeters at 4 weeks and 52 weeks after baseline baseline, 4 weeks, 52 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2